WANA (Jan 06) – An Iranian technology company has developed a platform based on nano-bubbles and ultrasound for treating Alzheimer’s disease. Research findings indicate that this platform enhances the effectiveness of therapeutic drugs by allowing them to cross the blood-brain barrier.

 

Mohammad-Javad Karimzadeh, CEO of the technology company, explained that their company is active in developing a platform for innovative Alzheimer’s treatment. He elaborated, “We have developed a two-part platform, one part using focused ultrasound technology, and the other utilizing drug delivery via nano-bubbles.”

 

Karimzadeh explained the details of the platform, stating, “In this method, Alzheimer’s drugs are loaded onto nano-bubbles using a patented technology. After the drug is injected into the body, the focused ultrasound technology directs the drug to the target organ, the brain.”

 

He emphasized that the focused ultrasound waves temporarily and reversibly open the blood-brain barrier, which usually prevents drugs from reaching the brain. This mechanism allows the drug to reach the brain with greater ease.

 

“The key advantage of this therapeutic technology is that it significantly increases drug efficacy by directing it precisely to the affected area of the brain, which has been disrupted by Alzheimer’s. Additionally, this method prevents the drug from being distributed throughout the body,” Karimzadeh added.

 

He also noted that conventional drug treatments spread throughout the body, causing side effects in other organs. In contrast, their method ensures that the drug is delivered directly to the brain, thereby enhancing its effectiveness and minimizing side effects.

 

Karimzadeh further shared the results of their research, which involved testing the drug on mice. The findings showed that the technology effectively targeted the brain, unlike traditional treatments where the drug spreads throughout the abdominal area and other parts of the body.

 

The CEO concluded by mentioning that in the development of this platform, they used a type of Alzheimer’s drug that could be loaded onto nano-bubbles.

 

This disease is a progressive and incurable brain disorder that leads to a gradual decline in memory, thinking, and cognitive abilities. It predominantly affects elderly individuals, with symptoms typically appearing after the age of 65, although in some cases, it can start earlier, referred to as early-onset Alzheimer’s.

 

Symptoms of the disease include short-term memory loss, difficulty in thinking and decision-making, changes in personality and behavior, spatial and temporal disorientation, and a decline in communication abilities.

 

It occurs due to the accumulation of proteins such as amyloid and tau in the brain, which causes damage to nerve cells and interferes with communication between them. Factors such as aging, family history, genetics, poor diet, lack of physical activity, sleep disorders, and stress are also influential in the development of the disease.

 

Currently, there is no definitive cure for Alzheimer’s; however, treatments can help alleviate symptoms and slow disease progression. In this regard, one technology company has introduced a platform to improve drug effectiveness in the brain, aiming to prevent the advancement of the disease.